Aripiprazole lauroxil
- Generic Name
- Aripiprazole lauroxil
- Brand Names
- Aristada
- Drug Type
- Small Molecule
- Chemical Formula
- C36H51Cl2N3O4
- CAS Number
- 1259305-29-7
- Unique Ingredient Identifier
- B786J7A343
- Background
Aripiprazole lauroxil is a long-acting injectable atypical antipsychotic drug used in the treatment of schizophrenia in adult patients. It is a prodrug of aripiprazole, which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors .
...
- Indication
Aripiprazole lauroxil is indicated for the treatment of schizophrenia and related psychotic disorders.
- Associated Conditions
- Schizophrenia
- Associated Therapies
- -
C-Cog in Early Course Schizophrenia Study
- Conditions
- Interventions
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 60
- Registration Number
- NCT05662306
- Locations
- 🇺🇸
Jackson Memorial Hospital, Miami, Florida, United States
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
- Conditions
- Interventions
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 15
- Registration Number
- NCT04203056
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
- Conditions
- Interventions
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT02636842
- Locations
- 🇺🇸
Alkermes Investigative Site, Dallas, Texas, United States
🇺🇸Alkermes Investigational Site, Marlton, New Jersey, United States
A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT02634320
- Locations
- 🇺🇸
Alkermes Investigational Site, DeSoto, Texas, United States
An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
- First Posted Date
- 2014-12-19
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT02320032
- Locations
- 🇺🇸
Alkermes Investigational Site, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.